PHARMACOECONOMIC EVALUATION OF A DIFFERENTIATED DRUG SCREENING PROGRAM IN ALGERIA: A COST-CONSEQUENCE ANALYSISPHARMACOECONOMIC EVALUATION OF A DIFFERENTIATED DRUG SCREENING PROGRAM IN ALGERIA: A COST-CONSEQUENCE ANALYSIS
Author(s)
Insaf Hamdi, PharmD student1, Younes Zebbiche, PhD2.
1Faculty of pharmacy, university of health sciences, Faculty of pharmacy, university of health sciences, Algeria, 2Algerian Federation of Pharmacy, Algiers, Algeria.
1Faculty of pharmacy, university of health sciences, Faculty of pharmacy, university of health sciences, Algeria, 2Algerian Federation of Pharmacy, Algiers, Algeria.
OBJECTIVES: To estimate the economic burden of this differentiated programme from a public-payer perspective, incorporating a cost-consequences analysis and probabilistic sensitivity analysis.
METHODS: A pharmacoeconomic cost-consequences analysis (one-year time horizon) was conducted. Direct and indirect costs were modelled separately for each target population according to their specific screening modality. A Monte-Carlo simulation (n = 10,000 iterations) was applied to high-uncertainty parameters.
RESULTS: The estimated total annual direct cost of screening tests alone ranges from 4,985 to 9,660 million DZD. Incorporating analytical confirmation and the full cost structure (human resources 40-45%, reagents 25-30%, training 10-15%, logistics 8-10%, infrastructure 5-7%), the total annual programme cost is estimated between 18.6 and 52.2 billion DZD. Cost-per-detected-case (reagents only) ranges from DZD 43,250-155,333 for job seekers and driving-licence applicants, and DZD 99,500-522,000 for athletes (extended urine panel).
CONCLUSIONS: The differentiated approach is both more economical and ethically more justifiable than universal screening. The school component requires a formalised referral protocol involving both teachers and school physicians, with mandatory confirmation and therapeutic orientation prioritised over punitive measures.
METHODS: A pharmacoeconomic cost-consequences analysis (one-year time horizon) was conducted. Direct and indirect costs were modelled separately for each target population according to their specific screening modality. A Monte-Carlo simulation (n = 10,000 iterations) was applied to high-uncertainty parameters.
RESULTS: The estimated total annual direct cost of screening tests alone ranges from 4,985 to 9,660 million DZD. Incorporating analytical confirmation and the full cost structure (human resources 40-45%, reagents 25-30%, training 10-15%, logistics 8-10%, infrastructure 5-7%), the total annual programme cost is estimated between 18.6 and 52.2 billion DZD. Cost-per-detected-case (reagents only) ranges from DZD 43,250-155,333 for job seekers and driving-licence applicants, and DZD 99,500-522,000 for athletes (extended urine panel).
CONCLUSIONS: The differentiated approach is both more economical and ethically more justifiable than universal screening. The school component requires a formalised referral protocol involving both teachers and school physicians, with mandatory confirmation and therapeutic orientation prioritised over punitive measures.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE46
Topic
Economic Evaluation, Health Technology Assessment, Methodological & Statistical Research
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health (including addiction)